A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
A legfontosabb adatok
- Ki végzi
- Tulane University
- Hol
- Covington és New Orleans (Egyesült Államok)Mind a 4 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 10 fő vett részt
- Kezdés
- 2025. szept. 25.
- Befejezés
- 2026. szept. 28.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Topical roflumilast 0.3% foam
- A regiszteradat frissítve
- 2026. október 9.
Ki vehet részt
- Életkor
- 18 év – 90 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- Must understand the risks and the benefits/purpose of the study and provide signed and dated informed consent
- Must be 18 years at time of signing informed consent form
- Willing to participate in all required evaluations and procedures in the study including the ability to apply topical medication without difficulty
- Patients must have a diagnosis of HS based upon the clinical criteria of a history of more than or equal 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time
- Patients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II/III with active disease after an adequate trial of systemic antibiotics/hormonal/immunomodulatory or biologic therapy
- Patient is required to be on stable dose of concomitant therapy for at least 3 months before enrollment and throughout the study period
- Females of childbearing potential must have a negative urine pregnancy test at baseline visit and be on adequate contraception throughout the study time
Ki nem vehet részt
- Concomitant use of topical antibiotics, topical corticosteroids, resorcinol, benzoyl peroxide, vitamin D analogs, Hibiclens wash (except for emollients) within 1 week of enrollment
- Increasing or changing dosing for concurrent therapy agents within 90 days before study day 0 and during the study period
- Prior major surgery or major life-threatening medical illness within 2 weeks
- Any severe systemic illness requiring Intravenous (IV) antibiotics within the two weeks prior to initiation of the study drug
- Active substance abuse or a history of substance abuse within 6 months prior to screening
- Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer)
- History of any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major uncontrolled disease
- Active hepatitis B or C infection with detectible viral nucleic acid in the blood or known Human Immunodeficiency Virus (HIV) positivity
- Patients with known active malignancy
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- Pregnant or breastfeeding
Helyszínek itt: Egyesült Államok
- Lakeview HospitalCovington, Egyesült Államok
- Lakeside HospitalNew Orleans, Egyesült Államok
- LCMC Multi-speciality ClinicNew Orleans, Egyesült Államok
- University Medical CenterNew Orleans, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a phase 2a, open label study.
A teljes eredeti leírásKevesebb
As psoriasis and Hidradenitis Suppurativa (HS) share multiple inflammatory pathways, the investigators hypothesize that the use of topical roflumilast 0.3% foam is a safe and efficacious option as a monotherapy for patients with mild disease and as add-on therapy for maintenance and flares in patients with moderate to severe disease. The study will include correlative analysis to study gene expression profiling before and after therapy.
A vizsgálat csoportja
- HS patients armA vizsgált kezelés
Patients must have a diagnosis of HS based upon the clinical criteria of a history of more or equal than 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time. Patients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II/III with active disease after an adequate trial of systemic antibiotics/hormonal/immunomodulatory or biologic therapy.
Kezelés: Topical roflumilast 0.3% foam
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Open Label Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam as a Mono or add-on Therapy in the Treatment of Hidradenitis Suppurativa With Correlative Analysis.
- A regiszteradat frissítve
- 2026. október 9.